drugset / Trial / NCT01300819

Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms

NCT01300819

Phase 4 Completed 349 enrolled UCB Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study was to demonstrate that Rotigotine improves non-motor symptoms compared to Placebo in subjects with Parkinson's Disease.

Timeline

Start
2011-02
Primary completion
2012-10
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 2 mg Other
Subject Rotigotine Unknown 4 mg Other
Subject Rotigotine Unknown 6 mg Other
Subject Rotigotine Unknown 8 mg Other
Subject Rotigotine Unknown 16 mg Other

Indications